Serum sickness induced by alemtuzumab in a kidney-pancreas transplant recipient
| Autor: | Angelito F Yango, Giuliano Testa, Richard Ruiz, Bernard Fischbach, Bipin Bista, Hoylan Fernandez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
CD52
business.industry medicine.drug_class General Medicine medicine.disease Monoclonal antibody Kidney Transplantation Rash Hypersensitivity reaction Serum Sickness Antineoplastic Agents Immunological Nephrology Serum sickness Immunology medicine Humans Alemtuzumab Polyarthritis Rituximab Pancreas Transplantation medicine.symptom business medicine.drug |
| Zdroj: | Clinical Nephrology. 96:47-50 |
| ISSN: | 0301-0430 |
| DOI: | 10.5414/cn110449 |
| Popis: | Serum sickness is an immune-complex-mediated hypersensitivity reaction that was first noted in the early 1900s in patients receiving heterologous antisera, such as horse antitetanus or antidiphtheria serum. This condition is primarily self-limited; however, in its acute state, it can cause severe symptoms of fever, rash, polyarthritis, or polyarthralgias. In solid organ transplantation, this condition is frequently reported in association with the use of rabbit anti-thymocyte globulin and chimeric murine monoclonal antibodies such as rituximab. Alemtuzumab, designed as a humanized monoclonal antibody against CD52, is expected to be less immunogenic. Here, we report a case of serum sickness associated with alemtuzumab induction therapy in a kidney-pancreas dual-organ recipient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|